Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

N/A

Waitlist Available

Led By Yulin Ge, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 21 minutes

Awards & highlights

No Placebo-Only Group

Summary

This trial uses a special MRI scan to check if the blood-brain barrier in older adults is working properly. It targets those at risk of dementia or Alzheimer's Disease, as early changes in this barrier might indicate future brain problems.

Eligible Conditions

Alzheimer's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 21 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 21 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 21 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Blood-Brain Barrier (BBB) Permeability as Measured by GRASP DCE-MRI Sequence

Permeability Surface Area (PS) as Measured by GRASP DCE-MRI Sequence

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Cohort CExperimental Treatment3 Interventions

Amnestic mild cognitive impairment (aMCI) patients aged 65 and older. Participants in Cohort C will be matched by age and gender to participants in Cohort B. Participants in Cohort C will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 9 minutes of scan time.

Group II: Cohort BExperimental Treatment3 Interventions

Cognitively normal control participants aged 65 - 85 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.

Group III: Cohort AExperimental Treatment3 Interventions

Cognitively normal control participants aged 20 - 40 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Gadolinium-based Contrast Agent (GBCA) for MRI

2018

N/A

~30

3T Brain Scan

2018

N/A

~30